<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199325</url>
  </required_header>
  <id_info>
    <org_study_id>qpfff@126.com</org_study_id>
    <nct_id>NCT04199325</nct_id>
  </id_info>
  <brief_title>Probiotics for Gout / Hyperuricemia: Randomized, Double-blind, Intervention, Parallel Controlled, Multicenter</brief_title>
  <official_title>Probiotics for Gout / Hyperuricemia: A Randomized, Double-blind, Intervention, Parallel Controlled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Inner Mongolia Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under the premise of double-blind and non-interference clinical treatment, to evaluate the
      clinical efficacy and safety of probiotic Lactobacillus Zhang combined with routine treatment
      for gout hyperuricemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum uric acid level</measure>
    <time_frame>24 weeks</time_frame>
    <description>The serum uric acid level was standard-reaching rate at the end of 24 weeks(Percentage of patients whose serum uric acid level has decreased to less than 360umol / L )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum uric acid level at the 4、8、12、24 weeks</measure>
    <time_frame>4、8、12、24 weeks</time_frame>
    <description>the serum uric acid level and the percentage of patients with &lt; 360umol / L at the end of 4, 8, 12 and 24 weeks after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum uric acid decreased from baseline</measure>
    <time_frame>4、8、12、24 weeks</time_frame>
    <description>At the end of 4, 8, 12 and 24 weeks after treatment, the serum uric acid level decreased from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute attack of gout</measure>
    <time_frame>24 week</time_frame>
    <description>Number of acute gout attacks during 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>uric-acid-lowering drug</intervention_name>
    <description>Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects are eligible for inclusion in this study only if they meet all of the following
        criteria

          1. 18-70 years old, gender unlimited ；

          2. Previous history of gout ；

          3. According to the criteria of gout classification and diagnosis of EULAR / ACR in 2015；

          4. fasting serum uric acid ≥ 480 μ mol / L (8mg / dl)

        Exclusion Criteria:

        If the subjects meet any of the following criteria, they will not be selected ：

          1. Gout in the past two weeks ；

          2. Secondary hyperuricemia ；

          3. Patients with abnormal liver and kidney function (ALT, AST are 1.5 times higher than
             the normal value, Cr is 1.5 times higher than the upper limit of the normal value；

          4. WBC &lt; 4.0 × 109 / L, PLT &lt; 100 × 109 / L, HGB &lt; 90g / L, or other hematological
             diseases ；

          5. bad blood pressure control (BP＞160mmHg/100 mmHg)

          6. Type I diabetes or poorly controlled type II diabetes: fasting blood glucose ≥
             8.5mmol/l ；

          7. Patients with active peptic ulcer ；

          8. Patients with gastrointestinal cancer ；

          9. Patients with previous intestinal diseases such as lactose intolerance, irritable
             bowel syndrome, inflammatory bowel disease and habitual diarrhea ；

         10. Use of drugs that affect the metabolism or excretion of uric acid and cannot / cannot
             be stopped, including azathioprine, 6-mercaptopterin, thiazide diuretics, aspirin
             (more than 325mg / day) or other salicylates ；

         11. Those who need continuous prednisone treatment ；

         12. Those who need antibiotic treatment for infectious diseases ；

         13. Those with body mass index (BMI) greater than 30 ；

         14. people with alcoholism ；

         15. People with a history of allergy to Lactobacillus and its products or with high
             sensitive constitution ；

         16. Researchers who have received other drugs within 3 months before screening ；

         17. The people who are researchers thinks it is not suitable to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inner Mongolia Medical College Affiliated Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong-bin LI, M.D</last_name>
      <phone>+86 13948536552</phone>
      <email>lhbwb73@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gout</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

